🔴 We are now live with an engaging presentation by Dr. Melanie Janning, MD, University Medical Center Mannheim, Germany, exploring how advanced circulating tumor cell (CTC) technologies are transforming precision oncology beyond conventional cell counting.
Presentation: Beyond Enumeration: CTC Apheresis as an Enabler for Functional and Single-Cell Oncology
Circulating tumor cells (CTCs) offer a unique window into cancer progression, but their rarity has long limited their clinical and research applications. In this session, Dr. Janning is demonstrating how CTC apheresis is overcoming this challenge by enabling the collection of larger numbers of tumor cells for comprehensive molecular and functional analysis.
Drawing on her expertise in liquid biopsy, single-cell technologies, and translational oncology, Dr. Janning highlights how CTC apheresis supports single-cell profiling, functional assays, and detailed molecular characterization, providing deeper insights into tumor heterogeneity, metastatic potential, and mechanisms of therapy resistance.
The presentation also explores how these innovative approaches can improve biomarker discovery, guide personalized treatment strategies, and accelerate the translation of cutting-edge research into clinical practice, bringing precision medicine closer to patients.
This insightful session showcases the next generation of liquid biopsy technologies and their potential to redefine cancer diagnostics, therapeutic decision-making, and individualized oncology care.
We extend our sincere thanks to Dr. Melanie Janning for sharing her expertise and to our global audience for joining us in this exciting scientific exchange.
This conference is organized by Impact Research Communications (IRC)
More info: https://liquidbio.ircconferences.net/ | Advances in Liquid Biopsy
